Nephroprotective effect of vitamin E and bismuth combinationation in-Patients treated with cisplatin chemotherapy

Muhanad Salah Mowlood

doi:10.15218/zjms.2012.0019

Authors

Muhanad Salah Mowlood Department of Clinical biochemistry, College of Pharmacy, HMU, Erbil, Iraq

DOI:

https://doi.org/10.15218/zjms.2012.0019

Keywords:

Cisplatin, Side effects, Protective agents, Oxidative stress, nephrototoxicity

Abstract

Background and objectives: The objective of this study was to explore the optimal combination of agents with their doses used along with cisplatin for the protection of nephrototoxicity.

Method: This experiment was carried out on patients suffering from different types of solid tumors divided into two groups: control group receiving cisplatin in a dose of 90 mg/ m² and the studied group receiving cisplatin in a dose of 90 mg/m² with bismuth subcitrate (200mg/day) and vitamin E (400mg/day).Blood urea and serum creatinine were tested for the assessments of renal function.

Results: control patients showed a sustain and significant elevation in blood urea and serum creatinine level in comparison with baseline along the entire period of the study, P<0.05. Meanwhile, the effect of cisplatin was shown to be significantly decreased in patients received bismuth-vitamin E therapy (P<0.05) along the entire period of the study.

Conclusion: Bismuth and vitamin E in combination play a beneficial role for preventing cisplatin nephrototoxity. The potentiated actions for preventing cisplatin nephrototoxicity could be achieved via combined use of these agents.

Metrics

Metrics Loading ...

References

Ekborn A, LindbergA, Laurell G,Wallin I, Eksborg S, Ehrsson H:Ototoxicity,nephrotoxicity and pharmacokinetics of cisplatin and its Monohydrated complex in the guinea pig; Cancer Chemother Pharmacol, 2003;51:36–42.

Iraz M, KalciogluMT, Kizilay A, Karatas E: Aminoguanidine prevents ototoxicity induced by cisplatin in rats; Ann Clin Lab Sci, 2005;35(3):329–35.

Yao X, Panichpisal K, Kurtzman N, Nugent K. Cisplatin nephrotoxicity: a Review; Am J Med Sci, 2007;334(2):115–24.

Ali BH, Al Moundhri MS. Agents ameliorating or augmenting the Nephrotoxicity of cisplatin and other platinum compounds: a reviewof some recent research; Food Chem Toxicol, 2006;44(8):1173–83.

Blakley BW, Cohen JI, Doolittle ND, Muldoon LL, Campbell KC, Dickey DT, et al. Strategies for prevention of toxicity caused by platinum-based chemotherapy; Laryngoscope, 2002;112(11):1997– 2001.

Kim SH, Hong KO, Hwang JK, Park KK. Xanthorrhizol has a Potential to attenuate the high dose cisplatin-induced nephrotoxicity in mice; Food Chem Toxicol, 2005;43(1):117–22.

Hong KO, Hwang JK, Park KK, Kim SH. Phosphorylation of c-Jun N-terminal Kinases (JNKs) is involved in the preventive effect of Xanthorrhizol on cisplatin-induced hepatotoxicity; ArchToxicol, 2005;79(4):231–6.

Ramesh G, Reeves WB. TNF-alpha mediates chemokine and Cytokine expression and renal injury in cisplatin nephrotoxicity; J Clin Inves, 2002;110(6):835–42.

Xiao T, Choudhary S, Zhang W, Ansari NH, Salahudeen A. Possible involvement of oxidative stress in cisplatin-induced apoptosis in LLC-PK1 cells; J Toxicol Environ Health A, 2003;66(5):469–79.

Pratibha R, Sameer R, Rataboli PV, Bhiwgade DA, Dhume CY. Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats; Eur J Pharmacol, 2006;532(3):290–3.

Koc A, Duru M, Ciralik H, Akcan R, Sogut S. Protective agent, erdosteine, against cisplatin-induced hepatic oxidant injury in rats; Mol Cell Biochem, 2005;278(1–2):79–84.

Iraz M, Ozerol E, Gulec M, Tasdemir S, Idiz N, Fadillioglu E, et al: Protective effect of caffeic acid phenethyl ester (CAPE) administration on cisplatin-induced oxidative damage to liver in rat; Cell Biochem Funct, 2006;24(4):357– 61.

Kagi. J. H. R., and Kojima. Y. Chemistry and biochemistry of metallothionein. In: H.R. J. Kagi and Y. Kojima (eds.); Metallothionein II Basel: Birkhauser Verlag, 1987; 25-61.

Naganuma. A.. Satoh. M.. and Imura. N. Protective effect of Metallothionein inducing metals on lethal toxicity of a.v-diamminedichloroplatinum in mice; Toxicol. Lett.,1985;24:203-7.

Imura. N.. Satoh. M.. and Naganuma. A. Possible application of metallothionein in cancer therapy. In: C. D. Klaassen and K. T. Suzuki (eds.); Metallothionein in Biology and Medicine, Boca Raton. FL: CRC Press, 1992; 375-82.

Boogaard. P. J, Slikkerveer. A, Nagelkerke. J. F, and Mulder. G. J. The role of metallothionein in the reduction of cisplatin-induced nephrotoxicity by Bi'*-pretreat ment in the rat in vivo and in vitro; Biochem. Pharmacol, 1991;41: 369-75.

Zelazowski. A. J, Garvey. J. S, and Hoeschele, J. D. in vivo and in vitro binding of platinum to Metallothionein; Arch. Biochem. Biophys.,1984; 229: 246-52.

Leonetti C, Biroccio A, Gabellini C, Scarsella M, Maresca V, Flori E, et al. Alpha-tocopherol protects against cisplatin-induced toxicity Without interfering with antitumor efficacy; Int J Cancer, 2003;104:243–50.

Naziroglu M, Karaoglu A, Aksoy AO. Selenium and high dose Vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats; Toxicol, 2004; 195: 221-30.

Satoh M, Shimada A, Zhang B, Tohyama C. Renal toxicity caused By cisplatinum in glutathione-depleted metallothionein-null mice; Biochem Pharmacol, 2000;60(11):1729–34.

Hosokawa O, Okabe M, Saito S, Saito T, Kurasaki M. Protective role ofmetallothionein on DNA damage in rat kidney caused by cisdiamminedichloroplatinum; Pharmacol Toxicol, 2000;86(6):276–82.

Bakka. A, Endresen, L, Johnsen. A. B. S, Edminson P. D, and Rugstad. H. E. Resistance against ns-diamminedichloroplatinum in cultured cells with a high content of Metallothionein; Toxicol. Appi. Pharmacol,1981; 61: 215-26.

Kasahara, K. Fujiwara. Y, Nishino, K, Ohmori. T, Sugimoto, Y.Komiya, K. Matuda, T, and Saijor, N. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin; Cancer Res.,1991; 5:323- 24.

Zhang K, Chew M, Yang EB, Wong KP, Mack P. Modulation of Cisplatin cytotoxicity and cisplatin-induced DNA cross-links in HepG2 cells by regulation of glutathione-related mechanisms; Mol Pharmacol, 2001;59(4):837 –43.

Ikeda K, Miura K, Himeno S, Imura N, Naganuma A. Glutathione Content is correlated with the sensitivity of lines of PC12 cells to cisplatin with-out a corresponding change in the accumulation of platinum; Mol Cell Biochem, 2001;219(1–2):51–6.

Cherian MG, Howell SB, Imura N, Klaassen CD, Koropatnick J,Lazo JS,et al. Role of metallothionein in carcinogenesis; Toxicol Appl Pharmacol,1994;126(1):1–5.

Satoh M, Cherian MG, Imura N, Shimizu H. Modulation of resistance to anticancer drugs by inhibition of metallothionein synthesis; Cancer Res,1994; 54(20):5255–7.

Naganuma, A, Satoh. M, and Imura. N. Prevention of lethal and renal toxicity of cis-diamminedichloroplatinum(II) by induction of metallothionein synthesis without compromising its antitumor activity in mice; Cancer Res.,1987; 47: 983-87.

Kondo. Y, Satoh, M, Imura. N, and Akimoto. M. Effect of bismuth nitrate given in combination with cis-diamminedichloroplatinum(ll) on the antitumoractivity and renal toxicity of the latter in nude mice inoculated with humanbladder tumor; Cancer Chemother Pharmacol.,1991; 29: 19-23.

Satoh. M, Naganuma. A, and Imura. N. Metallothionein induction prevents toxic side effects of cisplatin and Adriamycin used in combination; Cancer Chem. Pharmacol., 1988;21: 176-78.

Satoh, M., Naganuma. A., and Imura. N. Involvement of cardiac metallothionein in prevention of Adriamycin induced lipid peroxidation in the heart; Toxicology, 1988;53: 231-37.

Imura. N.. Satoh. M.. and Naganuma. A.: Possible application of metallothionein in cancer therapy. In: C. D. Klaassen and K. T. Suzuki (eds.); Metallothionein in Biology and Medicine, Boca Raton. FL: CRC Press,1992; 375-82.

Satomi. N.. Sakurai. A.. Haranaka. R., and Haranaka. K.: Preventive effects of several chemicals against lethality of recombinant human tumor necrosis factor;J. Biol. Response Modif.,1988; 7: 54-64.

Satoh. M.. Miura. N., Naganuma. A.. Matsuzaki. N.. Kawamura. E.,and Imura. N.: Prevention of adverse effects of "y-ray irradiation by metallothionein induction by bismuth subnitrate in mice; Eur. J. Cancer Clin. Oncol.,1989; 25: 1727-31.

Naganuma. A., Satoh. M.. and Imura. N. Specific reduction of toxic side effectsof Adriamycin by induction of metallothionein in mice; Jpn. J. Cancer Res.,1988;79:406-11.

Mansour, H. H., Hafez, F. H., and N. M. Fahmy: Silymarin modulates.Cisplatin-induced oxidative stress and hepatotoxicity in rats; J. Biochem. Mol. Biol.,2006;39:656-61.

Pratibha, R., Sameer, R., Rataboli, P. V., Bhiwgade, D. A., and C. Y. Dhume.: Enzymatic studies of cisplatin-induced oxidative stress in hepatic tissue of rats; Eur. J. Pharmacol.,2006; 532: 290-93.

Antunes, L. M. G., Darin, J. D. C., and M. L. P. Bianchi. Protective effects of vitamin C against cisplatin-induced nephrotoxicity and lipid peroxidation in adult rats: a dose-dependant study; Pharmacol. Res.,2000; 41: 405-11.

Jordan, P., and M. Carmo-Fonseca. Molecular mechanisms involved in cisplatin cytotoxicity; Cell Mol. Life Sci.,2000; 57:1229–35.

Atasayar, S., Gurer-Orhan, H., Orhan, H., Gurel, B., Girgin, G., and H. Ozguneş. Preventive effect of aminoguanidine compared to vitamin E and C on cisplatin-induced nephrotoxicity in rats; Exp. Toxicol. Pathol.,2009; 61:23-32.

Antunes, L. M. G., Darin, J. D. C., and M. L. P. Bianchi. Effects of the antioxidants curcumin or selenium on cisplatin-induced nephrotoxicity and lipid peroxidation in rats; Pharmacol. Res.,2001; 43:145-50.

Naziroğlu, M., Karaoglu, A., and A. O. Askoy. Selenium and high dose vitamin E administration protects cisplatin-induced oxidative damage to renal, liver and lens tissues in rats; Toxicology, 2004; 195:221-30.

Halliwell, B, and J. M. C. Gutteridge. Free Radicals in Biology and Medicine, 4rd Ed. Oxford University Press, New York.2007.

Spallhoz, J. E: On the nature of selenium toxicity and carcinostatic activity; Free Radic. Biol. Med.,1994; 17:45-64.

Rybak, L. P., Whitworth, C., and S. Somani. Application of antioxidants and other agents to prevent cisplatin ototoxicity; Laryngoscope, 1999; 109:1740–4446. Caffrey, P. B., and G. D. Frenkel. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo; Cancer Chemother. Pharmacol.,2000; 46:74-78.